Impact of EGFR expression on colorectal cancer patient prognosis and survival

Annals of Oncology

Volumn 16, Issue 1, 2005, Pages 102-108

  Spano, Jean Philippe ^a,b   Lagorce, C ^b   Atlan, D ^c   Milano, G ^d   Domont, J ^a   Benamouzig, R ^b   Attar, A ^b   Benichou, J ^e   Martin, A ^b   Morere, J F ^b   Raphael, M ^b   Penault Llorca, F ^f   Breau, J L ^b   Fagard, R ^b   Khayat, D ^a   Wind, P ^e  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b AVICENNE HOSPITAL   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d CENTRE ANTOINE LACASSAGNE   (France)

^e Departement de Chirurgie Viscerale   (France)

^f Centre Anticancéreux   (France)

Author keywords

Colorectal carcinoma; EGFR expression; Therapeutic strategy; TNM

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; TISSUE SECTION; TUMOR BIOPSY;

EID: 19944426509     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi006     Document Type: Article

References (45)

1. Hawk ET, Linburg PJ, Viner JL. Epidemiology and prevention of colorectal cancer. Surg Clin North Am 2002; 82: 905-941.
2. Shepherd NA, Saraga EP, Love SB et al. Prognostic factors in colonic cancer. Histopathology 1989; 14: 613-620.
3. Skibber JM, Minsky BD, Hoff PM. Cancer of the colon. Cancers of the gastrointestinal tract. ln DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, 6th edition. Philadelphia, PA: Lippincott Williams and Wilkins 2001; 1216-1271.
4. Hendler F, Shum Siu A, Nanu L et al. Overexpression of EGF receptors in squamous tumors is associated with poor survival. J Cell Biochem 1988; (Suppl 12A) 105 (Abstr).
5. Sainsbury JRC, Farndon JR, Needham GK et al. Epidermal growth factor receptor as predictor of early recurrence of and death from breast cancer. Lancet 1987; 1: 1398-1402.
6. Bauchnecht T, Kohler M, Janz I et al. The occurrence of epidermal growth factor receptors and the characterization of EGF-like receptors and the characterization of EGF-like factors in human ovarian, endometrial, cervical and breast cancer. J Cancer Res Clin Oncol 1989; 115: 193-199.
7. Neal DE, Marsh C, Bennett MK et al. Epidermal growth factor receptors in human bladder cancer: comparisons of invasive and superficial tumors. Lancet 1985; 1: 366-368.
8. Ozawa S, Ueda M, Ando N et al. Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer 1989; 63: 2169-2173.
9. Pfeiffer D, Stellwag B, Pfeiffer A et al. Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix. Gynecol Oncol 1989; 33: 146-150.
10. Salomon D, Brandt R, Ciardiello F et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
11. Coffey RJ Jr, Goustin AS, Soderquist AM et al. Transforming growth factor alpha and beta expression in human colon cancer lines: implications for an autocrine model. Cancer Res 1987; 47: 4590-4594.
12. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990; 265: 7709-7712.
13. Yarden Y, Sliwkowski M. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
14. Baselga J. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. J Clin Oncol 2002; 20: 2217-2219.
15. Tong WM, Ellinger A, Sheinin Y et al. Epidermal growth factor receptor expression in primary cultured human colorectal carcinomas cells. Br J Cancer 1998; 77: 1792-1798.
16. Messa C, Russo F, Caruso MG et al. EGF, TGFα and EGF-R in human colorectal adenocarcinoma. Acta Oncologica 1998; 37: 285-289.
17. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on cancer stage IV colon adenocarcinoma. Cancer 2001; 92: 1331-1346.
18. Giralt J, Eraso A, Armengol M et al. Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2002; 54: 1460-1465.
19. Kawamoto T, Sato JD, Le A et al. Growth stimulation of A431 cells by EGF: identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 1983; 80: 1337-1341.
20. International Union Against Cancer (UICC). In Hermaek P, Hatter RVP, Sobin LH et al. (eds): TNM Classification of Malignant Tumors, 4th edition. Berlin: Springer-Verlag 1998.
21. Cox DR. Regression models and life table. J R Star Soc 1972; 34: 187-220.
22. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Star Assoc 1958; 53: 457-481.
23. Mantel N, Haenszel W. Chi-square with one degree of freedom: Extensions of the Mantel-Haenszel procedure. J Am Star Assoc 1963; 58: 690-700.
24. Radinsky R, Risin S, Fan Z et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995; 1: 19-31.
25. Waksal HW. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev 1999; 18: 427-436.
26. Formento JL, Francoual M, Formento P et al. Epidermal growth factor receptor assay: validation of a single point method and application to breast cancer. Breast Cancer Res Treat 1991; 17: 211-216.
27. Allred DC, Swanson PE. Testing for erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol 2000; 113: 171-175.
28. Saeki T, Salomon DS, Johnson GR et al. Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase with prognosis of human colorectal carcinomas. Jpn J Clin Oncol 1995; 25: 240-249.
29. Koenders PG, Peters WH, Wobbes T et al. Epidermal growth factor receptor levels are lower in carcinomatous than in normal colorectal tissue. Br J Cancer 1992; 65: 189-192.
30. Komuta K, Koji T, Izumi S et al. Expression of epidermal growth factor receptor messenger RNA in human colorectal carcinomas assessed by non-radioactive in-situ hybridization. Eur J Surg Oncol 1995; 21: 269-275.
31. Karameris A, Kanavaros P, Aninos D et al. Expression of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in gastric and colorectal carcinomas. An immunohistological study of 63 cases. Pathol Res Pract 1993; 189: 133-137.
32. Koretz K, Schlag P, Moller P. Expression of epidermal growth factor receptor in normal colorectal mucosa, adenoma, and carcinoma. Virchow Arch A Pathol Anat Histopathol 1990; 416: 343-349.
33. Prewett M, Hooper A, Bassi R et al. Growth of human colorectal carcinoma xenografts by anti-EGF receptor monoclonal antibody in combination with 5-fluorouracil or irinotecan. Proc Am Assoc Cancer Res 2001; 42: 287 (Abstr 1543).
34. Radinsky R. Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment. Cancer Metastasis Rev 1995; 14: 323-338.
35. McKay JA, Murray LJ, Curran S et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumors and lymph node metastases. Eur J Cancer 2002; 38: 2258-2264.
36. Steele RJ, Kelly P, Ellul B et al. Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 1990; 77: 1352-1354.
37. Steele RJ, Kelly P, Ellul B et al. Immunohistochemical detection of epidermal growth factor receptors on human colonic carcinomas. Br J Cancer 1990; 61: 325-326.
38. Moorghen M, Ince P, Finney KJ et al. Epidermal growth factor receptors in colorectal carcinoma. Anticancer Res 1990; 10: 605-611.
39. Yasui W, Sumiyoshi H, Hata J et al. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 1988; 48: 137-141.
40. Mendelsohn J. Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. J Natl Cancer Inst Monogr 1992; 13: 125-131.
41. O'Dwyer PJ, Benson AB. Epidermal growth factor receptor-targeted therapy in colorectal cancer. Sem Oncol 2002; 29 (Suppl 14): 10-17.
42. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-2799.
43. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
44. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
45. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.